隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究

张人子; 李晟; 王导新

doi:10.16016/j.2097-0927.202203147

您当前的位置：

首页 >

文章列表页 >

隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究

基础医学 | 更新时间：2026-01-09

- 隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究
- Effect and mechanism of cryptotanshinone on early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome in mice
- 陆军军医大学学报 2022年44卷第18期页码：1819-1825
- 作者机构：
  
  重庆 400010，重庆医科大学附属第二医院呼吸与危重症医学科
- 作者简介：
  
  [ 王导新，E-mail：wangdaoxin0163@163.com WANG Daoxin, E-mail: wangdaoxin0163@163.com
- 基金信息：
  
  国家自然科学基金面上项目(81670071)
- DOI：10.16016/j.2097-0927.202203147
  中图分类号： R285.5;R363.21;R563.8
- 收稿：2022-03-17，
  
  修回：2022-04-26，
  
  纸质出版：2022-09-30
- 稿件说明：
移动端阅览
张人子, 李晟, 王导新. 隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究[J]. 陆军军医大学学报, 2022,44(18):1819-1825.

Renzi ZHANG, Sheng LI, Daoxin WANG. Effect and mechanism of cryptotanshinone on early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome in mice[J]. Journal of Army Medical University, 2022, 44(18): 1819-1825.
张人子, 李晟, 王导新. 隐丹参酮减轻LPS诱导的ARDS小鼠早期肺纤维化及机制研究[J]. 陆军军医大学学报, 2022,44(18):1819-1825. DOI： 10.16016/j.2097-0927.202203147.

Renzi ZHANG, Sheng LI, Daoxin WANG. Effect and mechanism of cryptotanshinone on early pulmonary fibrosis in LPS-induced acute respiratory distress syndrome in mice[J]. Journal of Army Medical University, 2022, 44(18): 1819-1825. DOI： 10.16016/j.2097-0927.202203147.

摘要

目的

探讨隐丹参酮(cryptotanshinone，CTS)对脂多糖(lipopolysaccharide，LPS)诱导的急性呼吸窘迫综合征(acute respiratory distress syndrome，ARDS)小鼠的早期肺纤维化的影响及其可能的作用机制。

方法

将40只8周龄雄性C57BL/6J小鼠随机分为正常组、模型组、处理组、CTS组(

=10)。模型组采用气管滴注LPS(5 mg/kg)制备ARDS模型。处理组在ARDS建模前腹腔注射CTS(60 mg/kg) 预处理3 d，建模后再连续予以CTS 7 d。正常组和CTS组分别注射等体积的无菌磷酸盐缓冲液(phosphate-buffered saline，PBS)或CTS。末次给药24 h后处死小鼠，取支气管肺泡灌洗液(bronchoalveolar lavage fluid，BALF)及肺组织。通过HE染色、肺组织湿/干质量(wet-to-dry，W/D)比值、BALF中蛋白浓度和总细胞计数评估肺组织损伤情况；采用酶联免疫吸附试验(ELISA)检测BALF中炎症因子水平；通过Masson染色及羟脯氨酸(hydroxyproline，HYP)含量检测评估肺组织纤维化程度；利用免疫组化染色或Western blot检测VE-cadherin、CD31、波形蛋白(Vimentin)、α-平滑肌肌动蛋白(α-smooth muscle actin，α-SMA)的蛋白表达。

结果

与正常组比较，模型组的肺组织W/D、BALF中总细胞数胞计数和蛋白浓度升高，BALF中的TGF-β1、TNF-α、IL-1β、IL-6升高，IL-10降低(

0.05)，小鼠肺组织出现肺损伤和早期肺纤维化；HYP含量升高(

0.05)；Vimentin、α-SMA的表达升高，而VE-cadherin、CD31的表达隆低(

0.05)。与模型组比较，处理组的肺组织W/D、BALF中总细胞计数和蛋白浓度降低，BALF中的TGF-β1、TNF-α、IL-1β、IL-6降低，IL-10升高(

0.05)；肺损伤和早期肺纤维化程度明显减轻，肺损伤评分和肺纤维化程度评分降低(

0.05)；HYP含量显著降低(

0.05)；Vimentin、α-SMA的表达降低，但VE-cadherin、CD31的表达增强(

0.05)。

结论

CTS可能通过抑制LPS刺激后肺组织中的内皮间质转化(endothelial-to-mesenchymal transition，EndMT)过程从而减轻ARDS小鼠早期肺纤维化。

Abstract

Objective

To investigate the effects and underlying mechanism of cryptotanshinone (CTS) on early pulmonary fibrosis in mice with lipopolysaccharide (LPS)-induced acute respiratory distress syndrome (ARDS).

Methods

Forty male C57BL/6J mice (8 weeks old) were randomly divided into control group

model group

treatment group

and CTS group

with 10 mice in each group. A ARDS model was established by intratracheal instillation of LPS (5 mg/kg). The mice in the treatment group was intraperitoneally pretreated with CTS (60 mg/kg) for 3 d before modeling

followed by CTS administion for 7 consecutive days. Similarly

the mice of the control and CTS groups were injected with an equivalent volume of sterile phosphate-buffered saline (PBS) or CTS

respectively. The mice were sacrificed in 24 h after the last challenge

and bronchoalveolar lavage fluid (BALF) and lung tissues were collected. The injury of lung was observed with HE staining

lung wet-to-dry (W/D) ratio

total protein concentration and total cell number in BALF. The levels of inflammatory cytokines in BALF were determined by enzyme-linked immunosorbent assay (ELISA). The fibrosis of lung was characterized by Masson staining and content of hydroxyproline (HYP). The protein levels of VE-cadherin

CD31

Vimentin and α-smooth muscle actin(α-SMA) were detected by immunohistochemistry or Western blotting.

Results

Obviously increased lung W/D ratio and total protein concentration and total cell number in BALF

elevated contents of TNF-α

TGF-β1

IL-1β and IL-6 while reduced content of IL-10 in BALF were seen in the model group when compared with the control group (

0.05). Compared with the model group

the treatment group had significantly decreased lung W/D ratio and total protein concentration and total cell number in BALF

down-regulated levels of IL-1β

IL-6

TNF-α and TGF-β1 and up-regulated level of IL-10 in BALF (

0.05). In addition

CTS also ameliorated lung injury and early fibrosis

decreased lung injury and fibrosis score

and reduced HYP content in LPS-induced ARDS (

0.05)

up-regulated the VE-cadherin and CD31 levels

and suppressed the Vimentin and α-SMA levels (

0.05).

Conclusion

CTS alleviates LPS-induced early pulmonary fibrosis in ARDS mice

and its underlying mechanism may be related to the inhibition of endothelial-to-mesenchymal transition (EndMT).

关键词

Keywords

references

MATTHAYM A, ZEMANS R L, ZIMMERMAN G A, et al . Acute respiratory distress syndrome[J ] . Nat Rev Dis Primers, 2019, 5(1): 18. DOI: 10.1038/s41572-019-0069-0.

LIUQ M, CHU H Y, MA Y Y, et al . Salvianolic acid B attenuates experimental pulmonary fibrosis through inhibition of the TGF-β signaling pathway[J ] . Sci Rep, 2016, 6: 27610. D OI: 10.1038/srep27610.

HAMACHER J, LUCAS R, LIJNENH R, et al . Tumor necrosis factor-alpha and angiostatin are mediators of endothelial cytotoxicity in bronchoalveolar lavages of patients with acute respiratory distress syndrome[J ] . Am J Respir Crit Care Med, 2002, 166(5): 651-656. DOI: 10.1164/rccm.2109004.

RAGHU G, COLLARDH R, EGAN J J, et al . An official ATS/ERS/JRS/ALAT statement: idiopathic pulmonary fibrosis: evidence-based guidelines for diagnosis and management[J ] . Am J Respir Crit Care Med, 2011, 183(6): 788-824. DOI: 10.1164/rccm.2009-040GL.

MARSHALL R, BELLINGAN G, LAURENT G. The acute respiratory distress syndrome: fibrosis in the fast lane[J]. Thorax, 1998, 53(10): 815-817. DOI: 10.1136/thx.53.10.815.

DHAINAUTJ F, CHARPENTIER J, CHICHE J D. Transforming growth factor-beta: a mediator of cell regulation in acute respiratory distress syndrome[J]. Crit Care Med, 2003, 31(4 Suppl): S258-S264. DOI: 10.1097/01.CCM.0000057901.92381.75.

MAN S, SANCHEZ DUFFHUES G, TEN DIJKE P, et al . The therapeutic potential of targeting the endothelial-to-mesenchymal transition[J ] . Ang iogenesis, 2019, 22(1): 3-13. DOI: 10.1007/s10456-018-9639-0.

MAK X, LI C L, XU J B, et al . LncRNA Gm16410 regulates PM 2.5-induced lungendothelial-mesenchymal transition via the TGF-β1/Smad3/p-Smad3 pathway[J ] . Ecotoxicol Environ Saf, 2020, 205: 111327. DOI: 10.1016/j.ecoenv.2020.111327.

SUZUKI T, TADA Y J, NISHIMURA R, et al . Endothelial-to-mesenchymal transition in lipopolysaccharide-induced acute lung injury drives a progenitor cell-like phenotype[J ] . Am J Physiol Lung Cell Mol Physiol, 2016, 310(11): L1185-L1198. DOI: 10.1152/ajplung.00074.2016.

TANG Y, CHENY L, CHU Z, et al . Protective effect of cryptotanshinone on lipopolysaccharide-induced acute lung injury in mice[J ] . Eur J Pharmacol, 2014, 723: 494-500. DOI: 10.1016/j.ejphar.2013.10.019.

ZHANG Q Y, GAN C L, LIU H Y, et al . Cryptotanshinone reverses the epithelial-mesenchymal transformation process and attenuates bleomycin-induced pulmonary fibrosis[J ] . Phytother Res, 2020, 34(10): 2685-2696. DOI: 10.1002/ptr.6699.

ZHAO J L, PATEL J, KAUR S, et al . Sox9 and Rbpj differentially regulate endothelial to mesenchymal transition and wound scarring in murine endovascular progenitors[J ] . Nat Commun, 2021, 12(1): 2564. DOI: 10.1038/s41467-021-22717-9.

LIU D, ZENGB X, ZHANG S H, et al . Rosiglitazone, a peroxisome proliferator-activated receptor-gamma agonist, reduces acute lung injury in endotoxemic rats[J ] . Crit Care Med, 2005, 33(10): 2309-2316. DOI: 10.1097/01.ccm.0000183161.81503.7d.

ASHCROFT T, SIMPSONJ M, TIMBRELL V. Simple method of estimating severity of pulmonary fibrosis on a numerical scale[J]. J Clin Pathol, 1988, 41(4): 467-470. DOI: 10.1136/jcp.41.4.467.

BONAVENTURA A, VECCHIÉ A, DAGNA L, et al . Endothelial dysfunction and immunothrombosis as key pathogenic mechanisms in COVID-19[J ] . Nat Rev Immunol, 2021, 21(5): 319-329. DOI: 10.1038/s41577-021-00536-9.

GEORGEP M, WELLS A U, JENKINS R G. Pulmonary fibrosis and COVID-19: the potential role for antifibrotic therapy[J]. Lancet Respir Med, 2020, 8(8): 807-815. DOI: 10.1016/S2213-2600(20)30225-3.

BURNHAME L, JANSSEN W J, RICHES D W H, et al . The fibroproliferative response in acute resp iratory distress syndrome: mechanisms and clinical significance[J ] . Eur Respir J, 2014, 43(1): 276-285. DOI: 10.1183/09031936.00196412.

LI J, ZHENG Y, LI M X, et al . Tanshinone ⅡA alleviates lipopolysaccharide-induced acute lung injury by downregulating TRPM7 and pro-inflammatory factors[J ] . J Cell Mol Med, 2018, 22(1): 646-654. DOI: 10.1111/jcmm.13350.

LIU Z P, XU S W, HUANG X Y, et al . Cryptotanshinone, an orally bioactive herbal compound from Danshen, attenuates atherosclerosis in apolipoprotein E-deficient mice: role of lectin-like oxidized LDL receptor-1 (LOX-1)[J ] . Br J Pharmacol, 2015, 172(23): 5661-5675. DOI: 10.1111/bph.13068.

LO S H, HSU C T, NIU H S, et al . Cryptotanshinone inhibits STAT3 signaling to alleviate cardiac fibrosis in type 1-like diabetic rats[J ] . Phytother Res, 2017, 31(4): 638-646. DOI: 10.1002/ptr.5777.

MA Y Z, LI H, YUE Z B, et al . Cryptotanshinone attenuates cardiac fibrosis via downregulation of COX-2, NOX-2, and NOX-4[J ] . J Cardiovasc Pharmacol, 2014, 64(1): 28-37. DOI: 10.1097/FJC.0000000000000086..

GO ODMANR B, PUGIN J, LEE J S, et al . Cytokine-mediated inflammation in acute lung injury[J ] . Cytokine Growth Factor Rev, 2003, 14(6): 523-535. DOI: 10.1016/S1359-6101(03)00059-5.

ORFANOSS E, MAVROMMATI I, KOROVESI I, et al . Pulmonary endothelium in acute lung injury: from basic science to the critically ill[J ] . Intens Care Med, 2004, 30(9): 1702-1714. DOI: 10.1007/s00134-004-2370-x.

WIENER-KRONISHJ P, ALBERTINE K H, MATTHAY M A. Differential responses of the endothelial and epithelial barriers of the lung in sheep to Escherichia coli endotoxin[J ] . J Clin Invest, 1991, 88(3): 864-875. DOI: 10.1172/JCI115388.

HASHIMOTO N, PHANS H, IMAIZUMI K, et al . Endothelial-mesenchymal transition in bleomycin-induced pulmonary fibrosis[J ] . Am J Respir Cell Mol Biol, 2010, 43(2): 161-172. DOI: 10.1165/rcmb.2009-0031OC

SOHALS S. Endothelial to mesenchymal transition (EndMT): an active process in chronic obstructive pulmonary disease (COPD)?[J]. Respir Res, 2016, 17: 20. DOI: 10.1186/s12931-016-0337-4.

浏览量

下载量

CSCD

文章被引用时，请邮件提醒。

提交

工具集

关联资源

靶向抗ICAM-1的载伊马替尼和液态氟碳脂质体对内毒素诱导的急性肺损伤/急性呼吸窘迫综合征模型小鼠的治疗研究

Chromofungin调控自噬流改善脓毒症小鼠肺组织炎症损伤

维生素D对脂多糖诱导的小鼠急性肺损伤的影响

SIRT3在肺泡Ⅱ型上皮细胞氧化应激及线粒体生物合成中的作用及机制研究

MAVS功能丧失性突变导致抗病毒免疫缺陷：揭示病毒感染触发儿童泛发性脓疱性银屑病的新机制